Intramuscular ziprasidone for acute agitation in adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 3, 2004, Pages 464-470

  Hazaray, Emmeline ^a   Ehret, Jason ^a   Posey, David J ^a   Petti, Theodore A ^b   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; GUANFACINE; HALOPERIDOL; LORAZEPAM; METHYLPHENIDATE; OLANZAPINE; PEMOLINE; SERTRALINE; VALPROIC ACID; ZIPRASIDONE;

ADOLESCENT; AGITATION; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; CASE REPORT; COMORBIDITY; CONDUCT DISORDER; DRUG EFFECT; GENERALIZED ANXIETY DISORDER; HUMAN; IMMOBILIZATION; MALE; OPPOSITIONAL DEFIANT DISORDER; PSYCHOPHARMACOTHERAPY; SCHOOL CHILD; SOMNOLENCE; SYNCOPE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; AGGRESSION; CHILD; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PIPERAZINES; PSYCHOMOTOR AGITATION; THIAZOLES;

EID: 8144222776     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2004.14.464     Document Type: Article

References (42)

1. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL: Risperidone disruptive behavior study group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
2. American Academy of Child and Adolescent Psychiatry (AACAP): Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry 41(Suppl):4S-25S, 2002.
3. Brestan EV, Eyberg SM: Effective psychosocial treatments of conduct-disordered children and adolescents: 29 years, 82 studies, and 5,272 kids. J Clin Child Psychol 27:180-189, 1998.
4. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CTM: A randomized, controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248, 2001.
5. Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C.: Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 62:479-480, 2001.
6. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology (Berl) 155:128-134, 2001.
7. Damon SE, Webber JC: Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacol 11:285-288, 2001.
8. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000.
9. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM: A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239-250, 2001.
10. Geller B, Luby J: Child and adolescent bipolar disorder: A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 36:1168-1176, 1997.
11. Kazdin AE: Current treatments. In: Conduct disorders in children and adolescents. Kazdin AE (ed.). Newbury Park, CA: Sage Publications, 1987, pp. 73-95.
12. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA: Olanzapine versus haloperidol in children with autistic disorder: An open-pilot study. J Am Acad Child Adolesc Psychiatry 40:887-894, 2001.
13. Martin A, Koenig K, Scahill L, Bregman J: Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99-107, 1999.
14. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000.
15. McDougle CJ, Kem DL, Posey DJ: Case Series: Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921-927, 2002.
16. McDougle CJ, Stigler KA, Posey DJ: Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 64(Suppl 4):16-25, 2003.
17. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 21:389-397, 2001.
18. Measham TJ: The acute management of aggressive behavior in hospitalized children and adolescents. Can J Psychiatry 40:330-336, 1995.
19. New York State Office of Mental Health (NYSOMH) Work Group on Preventive and Restrictive Interventions: Management of out of control behavior in children and adolescents: A comprehensive training guide. Albany: New York Office of Mental Health, 1997, pp. 1-52, 63.
20. Pappadopulos E, Jensen PS, Schur SB, MacIntyre JC II, Ketner S, Van Orden K, Sverd J, Sardana S, Woodlock D, Schweitzer R, Rube D: "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 28:111-121, 2002.
21. Pappadopulos E, Macintyre JC II, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 42:145-161, 2003.
22. Patel NC, Sierk P, Dorson PG, Crismon ML: Experience with ziprasidone (letter). J Am Acad Child Adolesc Psychiatry 41:495, 2002.
23. Petti TA, Sallee R: Issues in childhood and adolescent psychopharmacology. In: Advances in learning and behavioral disabilities: Methodological issues in human psychopharmacology. Gadow KD, Poling AD (eds.). Greenwich, CT: JAI Press, 1986, pp. 281-311.
24. Petti TA, Mohr WK, Somers J, Sims L: Perceptions of seclusion and restraint by patients and staff in an intermediate-term care facility. J Child Adolesc Psychiatr Nurs 14:115-117, 2001.
25. Petti TA, Sims L, Somers J, Mohr WK, Haugh D: Reduction of seclusion and restraint: Implications from the Indianapolis experience. In: A system of care for children's mental health: Expanding the research base. Newman C, Liberton CJ, Kutash K, Friedman RM (eds.). Tampa FL: University of South Florida, 2002, pp. 441-443.
26. Petti TA, Stigler KA, Gardner-Haycox J, Dumlao S: Perceptions of P.R.N. Psychotropic medications by hospitalized child and adolescent recipients. J Am Acad Child Adolesc Psychiatry 42:434-441, 2003.
27. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. J Clin Psychopharmacol 19:37-44, 1999.
28. Procyshyn RM, Pande S, Tse G: New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 45:668-669, 2000.
29. Psychopharmacological Drugs Advisory Committee: FDA background document on zeldox (PDAC 0700.M01). Rockville, MD: Food and Drug Administration, 2000.
30. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337-343, 2002.
31. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
32. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB: Ziprasidone treatment of children and adolescents with Tourette's Syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299, 2000.
33. Sallee FR, Gilbert DL, Vinks AA, Miceli JJ, Robarge L, Wilner K: Pharmacodynamics of ziprasidone in children and adolescents: Impact on dopamine transmission. J Am Acad Child Adolesc Psychiatry 42:902-907, 2003.
34. Scahill L, Schwab-Stone M, Merikangas KR, Leckman JF, Zhang H, Kasl S: Psychosocial and clinical correlates of ADHD in a community sample of school-age children. J Am Acad Child Adolesc Psychiatry 38:976-984, 1999.
35. Schur SB, Sikich L, Findling RL, Malone RP, Crismon, ML, Derivan A, Macintyre JC II, Pappadopulos E, Greenhill L, Schooler N, Van Orden K, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: A review. J Am Acad Child Adolesc Psychiatry 42:132-144, 2003.
36. Selva KA, Scott SM: Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 138:936-938, 2001.
37. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A: Risperidone conduct study group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
38. Stigler KA, Potenza MN, McDougle CJ: Tolerability profile of atypical antipsychotics in children and adolescents. Paediatric Drugs 3:927-942, 2001.
39. Tardiff K: Use of emergency medication. In: Assessment and management of violent patients, 2nd ed. Washington, DC: American Psychiatric Press, 1996, pp. 53-60.
40. Turetz M, Mozes T, Toren P, Chernauzan N, Yoran-Hegesh R, Mester R, Wittenberg N, Tyano S, Weizman A: An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 170:507-510, 1997.
41. Weller EB, Rowan A, Elia J, Weller RA: Aggressive behavior in patients with attention deficit hyperactivity disorder, conduct disorder, and pervasive developmental disorders. J Clin Psychiatry 60(Suppl 15):5-11, 1999.
42. Ziprasidone (Geodon) (ziprasidone hydrochloride) package insert 2002.